27 Sep Why Is Big Pharma Investing in Psychedelic Medicine?
Psychedelic medicine used to sound like a fringe conversation. Now companies including Eli Lilly and AbbVie are investing in treatments inspired by psychedelic research.
That is a big change. It also raises a fair question: Does a pharmaceutical company’s investment mean these treatments are proven?
No. It means researchers see enough potential to keep studying them. Clinical trials still need to establish which treatments work, for whom, and under what conditions. And research on a specific investigational drug does not tell us that every mushroom product has the same effects.
Our friends at Learn Euphoria break down what the investments mean, how compounds under study differ from one another, and why education matters as this field grows.
This article is for education and is not medical advice.
No Comments